OTREXUP TOTAL CARE CO-PAY ASSISTANCE MAIL-IN REBATE

If your pharmacist is unable to provide the co-pay or coinsurance savings at the time you fill your prescription, you can still take advantage of this program if eligible*.

A. Complete this form with your name and address.
B. Circle the product name, date, your name, and amount paid on the original pharmacy receipt. (Cash register receipt NOT accepted.)
C. Mail this form, your pharmacy receipt and a copy of your Otrexup Total Care Co-Pay Assistance Card to:

OTREXUP TOTAL CARE CO-PAY ASSISTANCE PROGRAM
2250 Perimeter Park Dr. Ste. 300
Morrisville, North Carolina 27560

First Name _____ **Last Name** _____

Address _____

City _____ **State** _____ **Zip** _____

Phone _____ **Email** _____

If you have any questions, please feel free to call 1-855-202-5711. ***Eligibility Restrictions:** See eligibility requirements at www.Otrexup.com.

Indications and Important Safety Information (ABBREVIATED) Including Boxed Warning

Indications
Otrexup is indicated in the management of selected adults with severe, active rheumatoid arthritis (RA) (ACR criteria), or children with active polyarticular juvenile idiopathic arthritis (pJIA), who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs).

Control the symptoms of severe, resistant, disabling psoriasis in adults when other types of treatment have been used and did not work well.

Otrexup should not be used for the treatment of cancer.

Otrexup should not be used for the treatment of children with psoriasis.

WARNING: SEVERE TOXIC REACTIONS, INCLUDING EMBRYO-FETAL TOXICITY AND DEATH

Serious toxic reactions and deaths have been reported with the use of methotrexate. Patients should be closely monitored for bone marrow, liver, lung, skin, and kidney toxicities.

Please see additional Important Safety Information on following page, and full Prescribing Information, including Boxed Warning, available at www.Otrexup.com.

Indications and Important Safety Information (ABBREVIATED) Including Boxed Warning *(continued)*

- **Methotrexate has been reported to cause fetal death and/or congenital anomalies, and is contraindicated in pregnancy.**
- **Methotrexate elimination is reduced in patients with impaired renal functions, ascites, or pleural effusions.**
- **Unexpectedly severe (sometimes fatal) bone marrow suppression, aplastic anemia, and gastrointestinal toxicity have been reported with concomitant administration of methotrexate along with some NSAIDs.**
- **Hepatotoxicity, fibrosis and cirrhosis may occur after prolonged use.**
- **Methotrexate may cause interstitial pneumonitis at any time during therapy and has been reported at low doses. Pulmonary symptoms (especially a dry, nonproductive cough) may require interruption of treatment and careful investigation.**
- **Diarrhea, ulcerative stomatitis, hemorrhagic enteritis and death from intestinal perforation may occur.**
- **Malignant lymphomas, which may regress following withdrawal of methotrexate, may occur.**
- **Severe, occasionally fatal, skin reactions have been reported.**
- **Potentially fatal opportunistic infections may occur.**

Contraindications

- **Pregnancy**
- **Nursing mothers**
- **Alcoholism or liver disease**
- **Immunodeficiency syndromes**
- **Preexisting blood dyscrasias**
- **Hypersensitivity to methotrexate**

Warnings and Precautions:

Organ system toxicity: Potential for serious toxicity. Only for use by physicians experienced in antimetabolite therapy.

Embryo-fetal toxicity: Exclude pregnancy before treatment. Avoid pregnancy if either partner is receiving Otrexup. Advisemales to avoid pregnancy for at least 3 months after therapy and females to avoid pregnancy for at least 1 ovulatory cycleafter therapy.

Effects on reproduction: May cause impairment of fertility, oligospermia and menstrual dysfunction.

Laboratory tests: Monitor complete blood counts, renal function and liver function tests.

Risks from improper dosing: Mistaken daily use has led to fatal toxicity.

Patients with impaired renal function, ascites, or pleural effusions: Elimination is reduced.

Dizziness and fatigue: May impair ability to drive or operate machinery.

Adverse Reactions

Common adverse reactions are: nausea, abdominal pain, dyspepsia, stomatitis/mouth sores, rash, nasopharyngitis, diarrhea, liver function test abnormalities, vomiting, headache, bronchitis, thrombocytopenia, alopecia, leucopenia, pancytopenia, dizziness, photosensitivity, and “burning of skin lesions.”

Please see additional Important Safety Information and full Prescribing Information, including Boxed Warning, available at www.Otrexup.com.

antares pharma

 January 2018 **OTX 451-18-01**